Muh. Akbar Bahar

Dr. Muh. Akbar Bahar

Universitas Hasanuddin
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2017 in Pharmacogenomics
Verified
Journal Article
Closed access
MBMuh. Akbar Bahar
Muh. Akbar Bahar
DSDidik Setiawan
Didik Setiawan
EHEelko Hak
Eelko Hak
BWBob Wilffert
Bob Wilffert
Currently, most guidelines on drug–drug interaction (DDI) neither consider the potential effect of genetic polymorphism in the strength of the interaction nor do they account for the complex interaction caused by the combination of DDI and drug–gene interaction (DGI) where there are multiple biotransformation pathways, which is referred to as drug–drug–gene interaction (DDGI). In this systematic review, we report the impact of pharmacogenetics on DDI and DDGI in which three major drug-metabolizing enzymes – CYP2C9, CYP2C19 and CYP2D6 – are central. We observed that several DDI and DDGI are highly gene-dependent, leading to a different magnitude of interaction. Precision drug therapy should take pharmacogenetics into account when drug interactions in clinical practice are expected.

6 July 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
Firzan NainuFirzan Nainu
Firzan Nainu
AMAyu Masyita
Ayu Masyita
MBMuh. Akbar Bahar
Muh. Akbar Bahar
MRMuhammad Raihan
Muhammad Raihan
SPShajuthi Rahman Prova
Shajuthi Rahman Prova
Jesus Simal-GandaraJesus Simal-Gandara
Jesus Simal-Gandara
Bee products have long been used in traditional healing practices to treat many types of disorders, including cancer and microbial-related diseases. Indeed, several chemical compounds found in bee products have been demonstrated to display anticancer, antibacterial, antiviral, and antiparasitic properties. With the improvement of research tools and in view of recent advances related to bee products, this review aims to provide broad yet detailed insight into the pharmaceutical prospects of bee products such as honey, propolis, bee pollen, royal jelly, bee bread, beeswax, and bee venom, in the domain of cancer and infectious disease management. Available literature confirms the efficacy of these bee products in the alleviation of cancer progression, inhibition of bacterial and viral proliferation, and mitigation of parasitic-related symptoms. With such potentials, bioactive components isolated from the bee products can be used as an alternative approach in the long-run effort to improve humans’ health at a personal and community level.

1 March 2023 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
SKSilma Kaaffah
Silma Kaaffah
IKIkhwan Yuda Kusuma
Ikhwan Yuda Kusuma
FRFransiskus Samuel Renaldi
Fransiskus Samuel Renaldi
YLYovita Endah Lestari
Yovita Endah Lestari
APArik Dian Eka Pratiwi
Arik Dian Eka Pratiwi
MBMuh. Akbar Bahar
Muh. Akbar Bahar
Introduction: Tuberculosis (TB) is still a persistent health challenge in Indonesia and ranks high on the list of factors causing morbidity and mortality. Improving knowledge, attitudes, and perceptions (KAP) of the general community about TB can help to control the disease. Purpose: This study aimed to examine the KAP about TB in Indonesian society and investigate their sociodemographic determinants. Participants and Methods: An online cross-sectional survey in 34 provinces in Indonesia was carried out in June 2022. The scores of KAP were classified as low, moderate, and high. Bivariate and multivariate ordinal logistic regression were applied to identify the potential sociodemographic determinants of KAP. Adjusted odds ratio and 95% confidence interval (CI) for each determinant were provided. Results: Among the 3205 participants, 56.4%, 91%, and 38% had high scores on knowledge, attitude, and perception, respectively. Independent determinants of high knowledge were age (26– 35 years; adjusted odds ratio: 1.53 [95% CI: 1.19– 1.97]), marital status (married; adjusted odds ratio: 1.18 [95% CI: 1.00– 1.39]), and salary (middle income; adjusted odds ratio: 0.76 [95% CI: 0.63– 0.93]). Independent factors associated with high scores in attitude and perception were the residence location (village; adjusted odds ratio: 0.76 [95% CI: 0.59– 0.98]) and the occupation type (civil servant; adjusted odds ratio: 1.53 [95% CI: 1.09– 2.13]), respectively. Conclusion: Most Indonesians have a high knowledge and good attitude, although they have a moderate perception toward TB. Improving public awareness and health education with the right strategies is critical to reducing the country’s TB burden. Graphical Abstract:

24 September 2018 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
MBMuh. Akbar Bahar
Muh. Akbar Bahar
JKJasper Kamp
Jasper Kamp
SBSander D. Borgsteede
Sander D. Borgsteede
EHEelko Hak
Eelko Hak
BWBob Wilffert
Bob Wilffert
Aim: Metoprolol (a CYP2D6 substrate) is often co‐prescribed with paroxetine/fluoxetine (a CYP2D6 inhibitor) because the clinical relevance of this drug–drug interaction (DDI) is still unclear. This review aimed to systematically evaluate the available evidence and quantify the clinical impact of the DDI.Method: Pubmed, Web of Science, Cochrane Library and Embase were searched for studies reporting on the effect of the DDI among adults published until April 2018. Data on pharmacokinetics, pharmacodynamics and clinical outcomes from experimental, observational and case report studies were retrieved. The protocol of this study was registered in PROSPERO (CRD42018093087).Results: We found nine eligible articles that consisted of four experimental and two observational studies as well as three case reports. Experimental studies reported that paroxetine increased the AUC of metoprolol three to five times, and significantly decreased systolic blood pressure and heart rate of patients. Case reports concerned bradycardia and atrioventricular block due to the DDI. Results from observational studies were conflicting. A cohort study indicated that the DDI was significantly associated with the incidence of early discontinuation of metoprolol as an indicator of the emergence of metoprolol‐related side effects. In a case–control study, the DDI was not significantly associated with bradycardia.Conclusion: Despite the contradictory conclusions from the current literature, the majority of studies suggest that the DDI can lead to adverse clinical consequences. Since alternative antidepressants and beta‐blockers with comparable efficacy are available, such DDIs can be avoided. Nonetheless, if prescribing the combination is unavoidable, a dose adjustment or close monitoring of the metoprolol‐related side effects is necessary.

28 September 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
Dorottya KonczDorottya Koncz
Dorottya Koncz
BTBarbara Tóth
Barbara Tóth
MBMuh. Akbar Bahar
Muh. Akbar Bahar
OROrsolya Roza
Orsolya Roza
Dezső CsuporDezső Csupor
Dezső Csupor
Synephrine has been used to promote weight loss; however, its safety and efficacy have not been fully established. The goals of our study were to give an overview of the safety and efficacy of p-synephrine, to systematically evaluate its efficacy regarding weight loss and to assess its safety, focusing on its cardiovascular side effects in a meta-analysis. PubMed, the Cochrane Library, Web of Science and Embase were searched for relevant studies. Only placebo-controlled, human clinical trials with synephrine intervention were included in the meta-analysis. The meta-analysis was reported according to the PRISMA guidelines using the PICOS format and taking into account the CONSORT recommendations. Altogether, 18 articles were included in the meta-analysis. Both systolic and diastolic blood pressure (DBP) increased significantly after prolonged use (6.37 mmHg, 95% CI: 1.02–11.72, p = 0.02 and 4.33 mmHg, 95% CI: 0.48–8.18, p = 0.03, respectively). The weight loss in the synephrine group was non-significant after prolonged treatment, and it did not influence body composition parameters. Based on the analyzed clinical studies, synephrine tends to raise blood pressure and heart rate, and there is no evidence that synephrine can facilitate weight loss. Further studies are needed to confirm evidence of its safety and efficacy.

22 December 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
NHNurhasni Hasan
Nurhasni Hasan
JLJuho Lee
Juho Lee
HAHye-Jin Ahn
Hye-Jin Ahn
WHWook Ryol Hwang
Wook Ryol Hwang
MBMuh. Akbar Bahar
Muh. Akbar Bahar
Jin-Wook YooJin-Wook Yoo
Jin-Wook Yoo
Polymicrobial wound infections are a major cause of infectious disease-related morbidity and mortality worldwide. In this study, we prepared a nitric oxide (NO)-releasing oxidized bacterial cellulose/chitosan (BCTO/CHI) crosslinked hydrogel to effectively treat polymicrobial wound infections. Linear polyethyleneimine diazeniumdiolate (PEI/NO) was used as the NO donor. The aldehyde group of BCTO and the amine of CHI were used as crosslinked hydrogel-based materials; their high NO loading capacity and antibacterial activity on the treatment of polymicrobial-infected wounds were investigated. The blank and NO-loaded crosslinked hydrogels, namely BCTO-CHI and BCTO-CHI-PEI/NO, were characterized according to their morphologies, chemical properties, and drug loading. BCTO-CHI-PEI/NO exhibited sustained drug release over four days. The high NO loading of BCTO-CHI-PEI/NO enhanced the bactericidal efficacy against multiple bacteria compared with BCTO-CHI. Furthermore, compared with blank hydrogels, BCTO-CHI-PEI/NO has a favorable rheological property due to the addition of a polymer-based NO donor. Moreover, BCTO-CHI-PEI/NO significantly accelerated wound healing and re-epithelialization in a mouse model of polymicrobial-infected wounds. We also found that both crosslinked hydrogels were nontoxic to healthy mammalian fibroblast cells. Therefore, our data suggest that the BCTO-CHI-PEI/NO developed in this study improves the efficacy of NO in the treatment of polymicrobial wound infections.